These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical experience with Fluosol-DA (20%) in the United States. Tremper KK; Levine EM; Waxman K Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514 [No Abstract] [Full Text] [Related]
3. Perfluorochemical emulsion oxygen transport fluids: a clinical review. Tremper KK; Anderson ST Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055 [TBL] [Abstract][Full Text] [Related]
5. The protective effect of mannitol and perfluorochemicals on hemorrhagic infarction: an experimental study. Kagawa S; Koshu K; Yoshimoto T; Suzuki J Surg Neurol; 1982 Jan; 17(1):66-70. PubMed ID: 6803373 [No Abstract] [Full Text] [Related]
6. Fluosol DA-20% in treatment of severe anemia: ongoing studies in 52 patients. Spence RK; McCoy S; Costabile J; Norcross ED; Pello M; Alexander J; Atabek U; Wisdom C; Camishion R Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):1069. PubMed ID: 1391428 [No Abstract] [Full Text] [Related]
7. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Kerins DM Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713 [No Abstract] [Full Text] [Related]
8. Which is the foreseeable clinical application of oxygen-carrying blood substitutes (fluorocarbons and hemoglobin solutions)? Which impact are they likely to have on the activity of blood services? Vox Sang; 1982 Feb; 42(2):97-109. PubMed ID: 7064434 [No Abstract] [Full Text] [Related]
9. Perfluorochemicals: artificial blood. Smith S Dimens Crit Care Nurs; 1984; 3(4):198-206. PubMed ID: 6563996 [No Abstract] [Full Text] [Related]
10. Medical oxygen transport using perfluorochemicals. Kaufman RJ Biotechnology; 1991; 19():127-62. PubMed ID: 1786469 [No Abstract] [Full Text] [Related]
11. Fluosol DA and oxygen as an adjuvant to the radiotherapeutic management of advanced head/neck carcinoma. Lustig RA; Rose CM; McIntosh-Lowe NL Biomater Artif Cells Artif Organs; 1988; 16(1-3):511-8. PubMed ID: 3179488 [No Abstract] [Full Text] [Related]
13. The use of fluorocarbon emulsions in cancer radiotherapy. Guichard M Radiother Oncol; 1991; 20 Suppl 1():59-64. PubMed ID: 2020771 [TBL] [Abstract][Full Text] [Related]
14. Can "artificial blood' live up to public billing? Cowart VS JAMA; 1982 Feb; 247(8):1104-5. PubMed ID: 7057595 [No Abstract] [Full Text] [Related]
15. Prophylaxis and treatment of myocardial ischaemia by haemodilution with fluorocarbon emulsions. Faithful NS; Fennema M; Erdmann W Adv Exp Med Biol; 1987; 215():89-95. PubMed ID: 3673746 [No Abstract] [Full Text] [Related]
16. Development and clinical application of perfluorochemical artificial blood. Ohyanagi H; Saitoh Y Int J Artif Organs; 1986 Sep; 9(5):363-8. PubMed ID: 3781670 [TBL] [Abstract][Full Text] [Related]
18. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients. Stefaniszyn HJ; Wynands JE; Salerno TA J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576 [TBL] [Abstract][Full Text] [Related]
19. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog. Biro GP Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307 [No Abstract] [Full Text] [Related]